Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer?

Molecular Cancer Therapeutics

Volumn 3, Issue 8, 2004, Pages 1031-1039

  Hull, Mark A ^a   Ko, Stanley C W ^a   Hawcroft, Gillian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR BLOCKING AGENT; PROSTAGLANDIN E RECEPTOR STIMULATING AGENT; PROSTAGLANDIN E1 RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; EPITHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LARGE INTESTINE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RODENT; SHORT SURVEY; SIGNAL TRANSDUCTION; TOXICITY TESTING;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DINOPROSTONE; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 4444291042     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (90)

1. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
2. Ota S, Bamba H, Kato A, Kawamoto C, Yoshida Y, Fujiwara K. COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther 2002;16 Suppl 2:102-6.
3. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5.
4. Gupta RA, DuBois RN. Controversy: PPARγ as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002;283: G266-9.
5. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
6. Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003;63:4872-7.
7. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-53.
8. Hawkey CJ. Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut 2002;50 Suppl III:25-30.
9. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003;278:19396-405.
10. 14C]-arachidonic acid by human colonic mucosa. Gut 1983; 24:1176-82.
11. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-3.
12. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518-23.
13. 2. Gut 1994; 35:675-8.
14. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
15. Chiu C-H, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-73.
16. Kubota Y, Sunouchi K, Ono M, Sawada T, Muto T. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 1992;35:645-50.
17. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
18. Min/+ mouse, a model for colon cancer. Cancer Res 2003;63:5136-42.
19. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997;94:657-62.
20. His LC, Baek SJ, Eling TE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 2000;250563-70.
21. Parker J, Kaplon MK, Alvarez CJ, Krishnaswamy G. Prostaglandin H synthase expression is variable in human colorectal adenocarcinomas cell lines. Exp Cell Res 1997;236:321-9.
22. Cutler NS, Graves-Deal R, LaFleur BJ, et al. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 2003;63:1748-51.
23. 2 by tissue-fixed macrophages in colonic carcinoma. Digestion 1990;47:160-6.
24. Breyer MD, Breyer RM. Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 2000;279:F12-23.
25. Takafuji V, Cosme R, Lublin D, Lynch K, Roche JK. Prostanoid receptors in intestinal epithelium: selective expression, function and change with inflammation. Prostaglandins Leukot Essent Fatty Acids 2000;63:223-35.
26. 2 receptor expression. Hum Immunol 2000;61:684-96.
27. Takafuji V, Lublin D, Lynch K, Roche JK. Mucosal prostanoid receptors and synthesis in familial adenomatous polyposis. Histochem Cell Biol 2001;116:171-81.
28. Morimoto K, Sugimoto Y, Katsuyama M, et al. Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 1997;272:G681-7.
29. Northey A, Denis D, Cirino M, Metters KM, Nantel F. Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract. Prostaglandins Other Lipid Mediat 2000;62:145-56.
30. Ding M, Kinoshita Y, Kishi K, et al. Distribution of prostaglandin E receptors in the rat gastrointestinal tract. Prostaglandins 199153: 199-216.
31. Narumiya S, Fitzgerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001;108:25-30.
32. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 2002;68-69:557-3.
33. Long JD, Orlando RC. Eicosanoids and the esophagus. Prostaglandins Other Lipid Mediat 2000;61:91-104.
34. Atay S, Tarnawski AS, Dubois A. Eicosanoids and the stomach. Prostaglandins Other Lipid Mediat 2000;61:105-24.
35. Mohajer B, Ma TY. Eicosanoids and the small intestine. Prostaglandins Other Lipid Mediat 2000;61:125-43.
36. Krause W, DuBois RN, Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat 2000;61:145-61.
37. 2 receptors. Proc Natl Acad Sci USA 1998;95:15792-7.
38. Namba T, Sugimoto Y, Negishi M, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993;365:166-70.
39. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003; 99:25-44.
40. 2. J Biol Chem 2002; 277-2614-9.
41. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003;74:143-53.
42. Wong NACS, Pignatelli M. β-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:380-401.
43. 2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151-6.
44. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
45. 2 regulated cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
46. 2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003;63:5218-23.
47. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63:2330-4.
48. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215-23.
49. 1 on three human colon carcinoma cell lines. Prostaglandins Leukot Essent Fatty Acids 1992; 47:313-9.
50. 2+ mobilization and cAMP in HT-29 human colon adenocarcinomas cells. Cancer Lett 2000;152:217-22.
51. Lesuffleur T, Barbat A, Dussaulx E, Zweibaum A. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res 1990;50:6334-43.
52. 2 on proliferation of an intestinal goblet cell line and its synthesis and secretion of mucin glycoproteins. Prostaglandins Leukot Essent Fatty Acids 1993;48:423-8.
53. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
54. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
55. Nishihara H, Kizaka-Kondoh S, Insel PA, Eckmann L. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 2003;100:8921-6.
56. Ko SCW, Chapple KS, Hawcroft G, Colette PL, Markham AF, Hull MA. Paracrine cyclooxygenase-2-mediated signaling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene 2002;21:7175-86.
57. Stange EF, Schneider A, Preclik G, Ditschuneit H. Prostaglandins are not involved in the differentiation or growth of cultured small intestinal cells. Digestion 1986;35:217-23.
58. 4 receptor. Gastroenterology 1999; 117:1352-62.
59. Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventative properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002;4:91-7.
60. Tutton PJM, Barkla DH. Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth. Br J Cancer 1988;41: 47-51.
61. 2 prostaglandins modulate cell proliferation in the small intestinal epithelium of the rat. Digestion 1992; 52:157-64.
62. Uribe A. Indomethacin accelerates clearance of labeled cells and increases DNA synthesis in the gastrointestinal mucosa of the rat. Dig Dis Sci 1992;37:403-8.
63. Min/+ mice. Cancer Res 2002; 62:O3-8.
64. 2 administration. Carcinogenesis 2003;24:985-90.
65. Wilson JW, Potten CS. The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 2000;60:4645-53.
66. 2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 1999;10:1851-60.
67. 4 in colon carcinogenesis. Cancer Res 2002; 62:28-32.
68. Δ716 knockout mice. Nat Med 2001;7:1048-51.
69. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-40.
70. 1 in colon carcinogenesis. Cancer Res 1999;59: 5093-6.
71. 1 selective antagonist ONO-8713 on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 2000;156:57-61.
72. Kitamura T, Kawamori T, Uchiya N, et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002;23:1463-6.
73. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventative activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
74. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998;19:1939-42.
75. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
76. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
77. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2000;61:1733-40.
78. Δ74 knockout mice. Carcinogenesis 2002;23:1351-9.
79. 4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2003;94:618-21.
80. Yamada Y, Yoshimi N, Hirose Y, et al. Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000;60:3323-7.
81. 2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-32.
82. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111:727-35.
83. Δ716 mouse intestinal polyps. Cancer Res 2002; 62:506-11.
84. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003;24: 524-9.
85. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50.
86. Narumiya S. Prostanoids in immunity: roles revealed by mice deficient in their receptors. Life Sci 2003;74:391-5.
87. Rocca B, Spain L, Pure E, Patrono C, Fitzgerald GA. Distinct and coordinated roles of prostaglandin H syntheses 1 and 2 in T-cell development. J Clin Invest 1999;103:1469-77.
88. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001;108:15-23.
89. Takeuchi K, Ukawa H, Kato S, et al. Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype EP3. Gastroenterology 1999;117:1128-35.
90. 2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003;278: 12752-8.